Edition:
United States

Consort Medical PLC (CSRT.L)

CSRT.L on London Stock Exchange

864.00GBp
8:12am EDT
Change (% chg)

-8.00 (-0.92%)
Prev Close
872.00
Open
860.00
Day's High
872.00
Day's Low
860.00
Volume
3,030
Avg. Vol
24,278
52-wk High
1,292.61
52-wk Low
700.00

Summary

Name Age Since Current Position

Christopher Brinsmead

59 2019 Non-Executive Chairman of the Board

Jonathan Glenn

47 2007 Chief Executive, Executive Director

Paul Hayes

51 2017 Chief Financial Officer, Executive Director

John Ilett

2015 Group General Counsel, Company Secretary

Keyvan Djamarani

Managing Director, Bespak

Ian Muir

Managing Director, Aesica

Steve Crummett

2012 Non-Executive Director

Charlotta Ginman

2015 Non-Executive Director

Andrew Hosty

53 2014 Non-Executive Director

Ian Nicholson

54 2012 Non-Executive Director

William Jenkins

71 2011 Senior Non-Executive Independent Director

Biographies

Name Description

Christopher Brinsmead

Mr. Christopher Brinsmead, CBE has been appointed as Non-executive Director and Chairman Designate of the Company, effective 7 February 2019. He is appointed as Non-Executive Chairman of the Board of the Company, effective 24 April 2019. Chris is currently the Senior Independent Non-executive Director of UDG Healthcare plc and a non-executive director of Collagen Solutions plc and The Wesleyan Assurance Society. In addition, Chris is a member of council at Imperial College London. Chris has worked in the global pharmaceutical sector for over thirty years, and has significant international, operational and strategic expertise. He was formerly the Chairman of AstraZeneca Pharmaceuticals UK, President of AstraZeneca UK and Ireland and President of the Association of the British Pharmaceutical Industry (ABPI). He has previously held Board positions at Domino Printing Sciences plc (2008-2016), Cambian Group plc (2014-2017) and Proteus Digital Health Inc (2010-2015).

Jonathan Glenn

Mr. Jonathan Glenn serves as a Chief Executive, Executive Director of Consort Medical plc. He was appointed Chief Executive in December 2007 and before that had been Group Finance Director since September 2006. Prior to joining Consort Medical plc, Jonathan was global Head of Finance at Celltech Group plc and later Chief Financial Officer of Akubio Ltd, a Cambridge-based developer of instrumentation for the life sciences industry. He is a member of the Institute of Chartered Accountants in England and Wales.

Paul Hayes

Mr. Paul Hayes serves as a Chief Financial Officer, Executive Director of the Company. Paul is an experienced finance director in multi-national high technology manufacturing, consumer goods and retail businesses. Paul has gained considerable experience during his five year tenure at The Vitec Group plc where he has built on his strong track record in operational management, delivering profitable growth and leading commercial, well-controlled finance functions. Previously, Paul was Group Financial Controller at Signet Jewellers Limited (formerly Signet Group plc) between 2007 and 2011. Prior to that, he held a senior director role at RHM plc from 2004 to 2007, assisting with its flotation in 2005 and subsequent sale to Premier Foods plc. Paul was with Smiths Group plc for over ten years from 1993, including a number of divisional and operating company finance director roles. Paul is a Chartered Accountant having qualified with Ernst and Young and has a first class Masters degree in Mechanical Engineering, Manufacture & Management.

John Ilett

Mr. John W. Ilett serves as Group General Counsel and Company Secretary of the Company, with effect from 3 November 2015. John has over 20 years of experience in the pharmaceutical/life sciences sector and brings a wealth of experience to the position from previous senior legal roles. These include at LGC Group Limited where he was General Counsel and Company Secretary from 2010 to 2015, and senior legal roles at Biomarin Pharmaceutical, Inc., Cephalon, Inc., Oxford Glycosciences plc and British Biotech plc. John also worked in private practice for several years at Stringer Saul (now Faskens). John is a qualified solicitor.

Keyvan Djamarani

Dr Keyvan Djamarani serves as a Managing Director, Bespak of the Company. He has over 15 years of experience at Consort Medical having previously held general management roles at Bespak Europe in the UK and Bespak Inc. in the US as well as a short appointment at Kings Systems Inc. prior to its disposal in 2013. Previously Keyvan held various project and production management roles at Unilever UK’s Detergents & Household Products and Personal Products Divisions.

Ian Muir

Dr Ian Muir serves as a Managing Director, Aesica of the Company. Mr. Ian holds a PhD in Pharmaceutical Science and has over 20 years’ experience in the pharmaceutical industry working for Wyeth, Mayne Pharma and BMS in Europe, the US and Australia, with significant senior operational and commercial experience over the past ten years in contract manufacturing roles for RP Scherer, Cardinal Health and Catalent where he has been responsible for leading both R&D activities and commercial manufacturing operations. In Ian’s most recent role prior to joining Aesica, he was responsible for the global provision of contract development and manufacturing services of oral dose forms.

Steve Crummett

Mr. Steve Crummett serves as a Non-Executive Director of Consort Medical PLC., with effect from 13 June 2012. is Group Finance Director of Filtrona plc, a FTSE 250 company, having been appointed to the role in 2008. Previously Steve was Group Finance Director of Filtrona plc (now Essentra plc) from 2008 to 2012. From 2003 to 2006 Steve was Group Director, Mergers & Acquisitions at Exel plc and previously held senior finance roles with McKechnie plc and Logica plc. Mr Crummett is a Chartered Accountant

Charlotta Ginman

Ms. Maria Charlotta Ginman-Jones (known as Ms Charlotta Ginman) serves as a Non-Executive Director of Consort Medical Plc., with effect from 11 February 2015. Ms Ginman qualified as a Chartered Accountant at Ernst & Young before spending a career in investment banking and commercial organisations, principally in technology-related businesses. Ms Ginman began her career at Ernst & Young joining in 1989, and was then appointed to a series of senior roles in investment banking with JP Morgan, Deutsche Bank and UBS both in London and Singapore. Ms Ginman has also held senior roles within Nokia Corporation, including acting as Chief Financial Officer of its luxury mobile phone division Vertu Corporation Limited. Ms Ginman oversaw the successful sale of Vertu Corporation to a private equity group in 2012. Until 21 August 2014 Ms Ginman was a non-executive director of Wolfson Microelectronics plc. Ms Ginman is a Non-executive Director of Kromek Group plc, where she is the current Chairman of the Audit Committee, and is also a Non-executive Director of Pacific Assets Trust plc and Polar Capital Technology Trust plc.

Andrew Hosty

Mr. Andrew Hosty serves as a Non-Executive Director of the Company. Andrew Hosty is Chief Operating Officer at Morgan Advanced Materials plc, an appointment he has held since February 2013. Prior to this Andrew was Chief Executive Officer of Morgan Ceramics and joined the Morgan Advanced Materials plc Board in July 2010. Before this he held a number of senior positions within Morgan Advanced Materials. Andrew is also a non executive director of British Ceramic Research Limited. Previously Andrew was a non executive director of Fiberweb plc from 2012 to 2013 and President of the British Ceramics confederation from 2003 to 2005.

Ian Nicholson

Mr. Ian Nicholson serves as a Non-Executive Director of Consort Medical PLC. He has been Chief Executive of Chroma Therapeutics Limited, a drug discovery and development company since 2004. He is Chairman of Bioventix Ltd, a diagnostics company, and a Non-executive Director of Symphogen A/S, an antibody therapeutics company. From 2000 to 2004 Ian was Senior Vice President, Business Development at Celltech Group plc, then the UK's biotechnology company. He has experience in licensing, mergers and acquisitions, and market development in the UK, Europe and the US.

William Jenkins

Dr. William J. Jenkins, M.D., serves as Senior Non-Executive Independent Director of Consort Medical plc. He is a non-executive director of Ablynx nv, Allecra Therapeutics GmbH and AlloCyte Pharmaceuticals AG. He is also an ad hoc member of the board of Evotec AG and a member of their Scientific Advisory Board as well as a member of the Scientific Advisory Board of BB Biotech Ventures and a member of the Strategic Advisory Board of Chiesi Farmaceutici SpA. He is principal of William Jenkins Pharma Consulting.